Richard Rupp

Completed

A Phase III, partially modified double-blind, randomized, parallel-group, active-controlled, multi-center study to compare the immunogenicity and describe the safety of MenACYW conjugate vaccine and MENVEO? when administered concomitantly with routine pe

Rupp, R.

Sanofi Pasteur Inc

5/2/18 → 5/1/20

Project: Other project

An Expanded Access Treatment Protocol for Zmapp TM for Patients with Ebola Virus Disease (EVD) or Ebola Virus Exposure

Rupp, R.

ICON Government & Public Health Solution

5/1/18 → 6/26/19

Project: Other project

Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3- Dose Regimen of V160 (Cytomegalovirus [CMV] Vaccine) in Healthy Seronegative Women, 16 to 35

Rupp, R.

Merck Sharp & Dohme Corporation

4/24/18 → 4/23/20

Project: Other project

A PHASE 2, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS

Rupp, R.

Pfizer, Inc.

3/30/18 → 3/29/20

Project: Other project

Protocol 63623872FLZ3002: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Non-hospitalized

Rupp, R.

Janssen Pharmaceutica NV

2/5/18 → 12/31/19

Project: Other project

Protocol 63623872FLZ3002: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Non-hospitalized

Rupp, R.

Janssen Pharmaceutical Research & Develo

2/5/18 → 12/31/19

Project: Other project

A Phase 3, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 (PE34) Process Administered Concomitantly with M-M-R II

Rupp, R.

Merck Sharp & Dohme Corporation

8/21/17 → 8/20/19

Project: Other project

lmmunogenicity, reactogenicityan safetystudyof Pediarix, Hiberix, and Prevnar 13 co-administered with two diff'erent formulations of GSK Biologicals' HRVvaccine ( 444563) in healthy infants 6-12 weeks of age

Rupp, R.

GlaxoSmithKline Pharmaceuticals

8/18/17 → 8/17/19

Project: Other project

A Phase II, Double-Blind, Randomized, Multicenter Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar13? in Healthy Infants

Rupp, R.

Merck Sharp & Dohme Corporation

2/8/17 → 2/7/20

Project: Other project

GV29893 A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY, ADMINISTERED AS MONOTHERAPY FOR THE TREATMENT OF ACUTE UNCOMPLICATED SEASONAL INFLUENZA A INFECTION IN OTHERWISE HEALTHY ADULTS

Rupp, R.

Genentech, Inc.

10/27/16 → 10/26/18

Project: Other project

Vaccine and Treatment Evaluation Units (VTEU) Protocol Development, Implementation and Assays Task Area B-D Task Order 15-0066.B1C1D1.0041

Rupp, R.

BAYLOR COLLEGE OF MEDICINE

9/16/16 → 6/30/19

Project: Other project

V114-005 A Phase l-ll, randomized, Double-Blind, Study to Evaluate the safety, Tolerability, and Immunogenicity of Different formulations of V114 in Healthy Adults and Infants

Rupp, R.

Merck Sharp & Dohme Corporation

8/18/15 → 8/17/18

Project: Other project

A Phase III, Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Immunogenicity of Three Consistency Lots and a high Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults

Rupp, R.

Merck Sharp & Dohme Corporation

8/4/15 → 9/30/18

Project: Other project

V160-001-002: A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults

Rupp, R.

Merck Sharp & Dohme Corporation

6/27/14 → 6/26/18

Project: Other project

A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of VARIVAX New Seed Process (NSP) Administered Concomitantly with M-M-R II

Rupp, R.

Merck Sharp & Dohme Corporation

4/30/14 → 5/1/16

Project: Other project

V503-010-0007: A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose regimen of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, administered in Preadolescents and Adolescents (9 to 14 yea

Rupp, R.

Merck Sharp & Dohme Corporation

2/7/14 → 2/6/19

Project: Other project

V114-004 A Phase I-II, Randomized, Double-Blind, study to Evaluate the Safty, Tolerability, and Immunogenicity of V114 in Healthy Adults and Infants

Rupp, R.

Merck Sharp & Dohme Corporation

12/10/13 → 12/31/17

Project: Other project

Protocol No.: V503-003-00-0255: "A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillornavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year Old Men and 16- to 26-Year Old Women"

Rupp, R.

Merck Sharp & Dohme Corporation

1/3/13 → 1/2/15

Project: Other project

Phase 1b, Partial-Blind, Parallel Group, Randomized Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine (DENVax) Administered Intradermally Using Needle or a Needle-Free PharmaJet Injector in Healthy Adults

Rupp, R.

Takeda Vaccines Inc

12/31/12 → 12/14/16

Project: Other project

Protocol No.: V221-027; A Phase III Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, Varicella (MMRV) Vaccine Made with Alternative Manufacturing Process (AMP)

Rupp, R.

Merck Sharp & Dohme Corporation

6/21/12 → 6/20/14

Project: Other project

Protocol No.: V59P23; "A Phase 3b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine when Administered with Routine Infant Vaccinations to Healthy Infants"

Rupp, R.

Novartis Vaccines & Diagnostics Inc

4/27/12 → 4/26/14

Project: Other project

Protocol: V114-002-008, "A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of a Pneumococcal Conjugate Vaccine (V114) Compared to Pneumococcal Polysaccharide Vaccine (PNEUMOVAX 23) and Prevnar 13 (Pneumococcal 13-Valent

Rupp, R.

Merck Sharp & Dohme Corporation

3/1/12 → 6/14/19

Project: Other project

Protocol Number: INV-DEN-104; A Randomized, Phase 1b Study to Investigate the Safety and Immunogenicty of Various Schedules of Tetravalent Chimeric Dengue Vaccine in Healthy Adult Volunteers Between the Ages of 18-45 Years

Rupp, R.

Takeda Vaccines Inc

12/20/11 → 9/1/15

Project: Other project

Protocol B1971011: A Phase 2, Randomized, Single-Blind Trial, To Asess the Safety, Tolerability and Immunogenicity of Gardasil Vaccine and rLP2086 Vaccine When Administered Concomitantly in Healthy Subjects Aged >/= 11 to </=17 Years

Rupp, R.

Pfizer, Inc.

8/1/11 → 1/1/15

Project: Other project

08-0013 Eval Control Measures

Rupp, R.

BAYLOR COLLEGE OF MEDICINE

7/1/09 → 8/31/17

Project: Other project

Protocol No. V59P13E1: A Phase 3, Open-Label,Multi-Center Study to Evaluate the Persistence of Novartis MenACWY Antibody Response in Adolescents who Have Previously received either Novartis MenACWY Conjugate Vaccine or Menactra

Rupp, R.

Novartis Vaccines & Diagnostics Inc

2/2/09 → 2/1/15

Project: Other project

Novartis V59P13: A Phase III, Randomized, Ovserver-blind, Controlled, Multi-Center Study to Evaluate the Lot to Lot Consistency of Novartis Meningococcal ACWY Conjugate Vaccine when One Dose is Administered to Healthy Adolescents 11-18 Years of Age and t

Rupp, R.

Novartis Pharmaceuticals Corporation

2/10/07 → 3/31/15

Project: Other project

Richard Rupp, MD

Projects

A Phase III, partially modified double-blind, randomized, parallel-group, active-controlled, multi-center study to compare the immunogenicity and describe the safety of MenACYW conjugate vaccine and MENVEO? when administered concomitantly with routine pe

An Expanded Access Treatment Protocol for Zmapp TM for Patients with Ebola Virus Disease (EVD) or Ebola Virus Exposure

Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3- Dose Regimen of V160 (Cytomegalovirus [CMV] Vaccine) in Healthy Seronegative Women, 16 to 35

A PHASE 2, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS

Protocol 63623872FLZ3002: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Non-hospitalized

Protocol 63623872FLZ3002: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Non-hospitalized

A Phase 3, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 (PE34) Process Administered Concomitantly with M-M-R II

lmmunogenicity, reactogenicityan safetystudyof Pediarix, Hiberix, and Prevnar 13 co-administered with two diff'erent formulations of GSK Biologicals' HRVvaccine ( 444563) in healthy infants 6-12 weeks of age

A Phase II, Double-Blind, Randomized, Multicenter Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar13? in Healthy Infants

GV29893 A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY, ADMINISTERED AS MONOTHERAPY FOR THE TREATMENT OF ACUTE UNCOMPLICATED SEASONAL INFLUENZA A INFECTION IN OTHERWISE HEALTHY ADULTS

Vaccine and Treatment Evaluation Units (VTEU) Protocol Development, Implementation and Assays Task Area B-D Task Order 15-0066.B1C1D1.0041

V114-005 A Phase l-ll, randomized, Double-Blind, Study to Evaluate the safety, Tolerability, and Immunogenicity of Different formulations of V114 in Healthy Adults and Infants

A Phase III, Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Immunogenicity of Three Consistency Lots and a high Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults

V160-001-002: A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults

A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of VARIVAX New Seed Process (NSP) Administered Concomitantly with M-M-R II

V503-010-0007: A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose regimen of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, administered in Preadolescents and Adolescents (9 to 14 yea

V114-004 A Phase I-II, Randomized, Double-Blind, study to Evaluate the Safty, Tolerability, and Immunogenicity of V114 in Healthy Adults and Infants

Protocol No.: V503-003-00-0255: "A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillornavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year Old Men and 16- to 26-Year Old Women"

Phase 1b, Partial-Blind, Parallel Group, Randomized Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine (DENVax) Administered Intradermally Using Needle or a Needle-Free PharmaJet Injector in Healthy Adults

Protocol No.: V221-027; A Phase III Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, Varicella (MMRV) Vaccine Made with Alternative Manufacturing Process (AMP)

Protocol No.: V59P23; "A Phase 3b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine when Administered with Routine Infant Vaccinations to Healthy Infants"

Protocol: V114-002-008, "A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of a Pneumococcal Conjugate Vaccine (V114) Compared to Pneumococcal Polysaccharide Vaccine (PNEUMOVAX 23) and Prevnar 13 (Pneumococcal 13-Valent

Protocol Number: INV-DEN-104; A Randomized, Phase 1b Study to Investigate the Safety and Immunogenicty of Various Schedules of Tetravalent Chimeric Dengue Vaccine in Healthy Adult Volunteers Between the Ages of 18-45 Years

Protocol B1971011: A Phase 2, Randomized, Single-Blind Trial, To Asess the Safety, Tolerability and Immunogenicity of Gardasil Vaccine and rLP2086 Vaccine When Administered Concomitantly in Healthy Subjects Aged >/= 11 to </=17 Years

08-0013 Eval Control Measures

Protocol No. V59P13E1: A Phase 3, Open-Label,Multi-Center Study to Evaluate the Persistence of Novartis MenACWY Antibody Response in Adolescents who Have Previously received either Novartis MenACWY Conjugate Vaccine or Menactra

Novartis V59P13: A Phase III, Randomized, Ovserver-blind, Controlled, Multi-Center Study to Evaluate the Lot to Lot Consistency of Novartis Meningococcal ACWY Conjugate Vaccine when One Dose is Administered to Healthy Adolescents 11-18 Years of Age and t